402 related articles for article (PubMed ID: 36594091)
1. Insights into the roles and pathomechanisms of ceramide and sphigosine-1-phosphate in nonalcoholic fatty liver disease.
Zhu C; Huai Q; Zhang X; Dai H; Li X; Wang H
Int J Biol Sci; 2023; 19(1):311-330. PubMed ID: 36594091
[TBL] [Abstract][Full Text] [Related]
2. Sphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover.
Simon J; Ouro A; Ala-Ibanibo L; Presa N; Delgado TC; Martínez-Chantar ML
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861664
[TBL] [Abstract][Full Text] [Related]
3. Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver Cancer.
Wang K; Wei Y; Xu R; Li Y; Mao C
Adv Exp Med Biol; 2022; 1372():157-168. PubMed ID: 35503180
[TBL] [Abstract][Full Text] [Related]
4. Ceramide de novo synthesis in non-alcoholic fatty liver disease: Pathogenic mechanisms and therapeutic perspectives.
Yu XD; Wang JW
Biochem Pharmacol; 2022 Aug; 202():115157. PubMed ID: 35777449
[TBL] [Abstract][Full Text] [Related]
5. Sphingolipid metabolism in non-alcoholic fatty liver diseases.
Régnier M; Polizzi A; Guillou H; Loiseau N
Biochimie; 2019 Apr; 159():9-22. PubMed ID: 30071259
[TBL] [Abstract][Full Text] [Related]
6. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.
Ooi GJ; Meikle PJ; Huynh K; Earnest A; Roberts SK; Kemp W; Parker BL; Brown W; Burton P; Watt MJ
J Hepatol; 2021 Sep; 75(3):524-535. PubMed ID: 33887358
[TBL] [Abstract][Full Text] [Related]
7. Sphingolipids at the Crossroads of NAFLD and Senescence.
Nikolova-Karakashian M
Adv Cancer Res; 2018; 140():155-190. PubMed ID: 30060808
[TBL] [Abstract][Full Text] [Related]
8. Specific Hepatic Sphingolipids Relate to Insulin Resistance, Oxidative Stress, and Inflammation in Nonalcoholic Steatohepatitis.
Apostolopoulou M; Gordillo R; Koliaki C; Gancheva S; Jelenik T; De Filippo E; Herder C; Markgraf D; Jankowiak F; Esposito I; Schlensak M; Scherer PE; Roden M
Diabetes Care; 2018 Jun; 41(6):1235-1243. PubMed ID: 29602794
[TBL] [Abstract][Full Text] [Related]
9. Effects of constant light exposure on sphingolipidomics and progression of NASH in high-fat-fed rats.
Yue F; Xia K; Wei L; Xing L; Wu S; Shi Y; Lam SM; Shui G; Xiang X; Russell R; Zhang D
J Gastroenterol Hepatol; 2020 Nov; 35(11):1978-1989. PubMed ID: 32027419
[TBL] [Abstract][Full Text] [Related]
10. Lipidomics in non-alcoholic fatty liver disease.
Kartsoli S; Kostara CE; Tsimihodimos V; Bairaktari ET; Christodoulou DK
World J Hepatol; 2020 Aug; 12(8):436-450. PubMed ID: 32952872
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic effect and autophagy regulation of myriocin in nonalcoholic steatohepatitis.
Yang RX; Pan Q; Liu XL; Zhou D; Xin FZ; Zhao ZH; Zhang RN; Zeng J; Qiao L; Hu CX; Xu GW; Fan JG
Lipids Health Dis; 2019 Oct; 18(1):179. PubMed ID: 31639005
[TBL] [Abstract][Full Text] [Related]
12. Roles of Ceramides in Non-Alcoholic Fatty Liver Disease.
Hajduch E; Lachkar F; Ferré P; Foufelle F
J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33669443
[TBL] [Abstract][Full Text] [Related]
13. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease.
Luukkonen PK; Zhou Y; Sädevirta S; Leivonen M; Arola J; Orešič M; Hyötyläinen T; Yki-Järvinen H
J Hepatol; 2016 May; 64(5):1167-1175. PubMed ID: 26780287
[TBL] [Abstract][Full Text] [Related]
14. Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease.
Svegliati-Baroni G; Pierantonelli I; Torquato P; Marinelli R; Ferreri C; Chatgilialoglu C; Bartolini D; Galli F
Free Radic Biol Med; 2019 Nov; 144():293-309. PubMed ID: 31152791
[TBL] [Abstract][Full Text] [Related]
15. Non-alcoholic fatty liver disease: Insights from sphingolipidomics.
Montefusco DJ; Allegood JC; Spiegel S; Cowart LA
Biochem Biophys Res Commun; 2018 Oct; 504(3):608-616. PubMed ID: 29778532
[TBL] [Abstract][Full Text] [Related]
16. The ketogenic diet prevents steatosis and insulin resistance by reducing lipogenesis, diacylglycerol accumulation and protein kinase C activity in male rat liver.
Jani S; Da Eira D; Stefanovic M; Ceddia RB
J Physiol; 2022 Sep; 600(18):4137-4151. PubMed ID: 35974660
[TBL] [Abstract][Full Text] [Related]
17. Too Much of a Good Thing? An Evolutionary Theory to Explain the Role of Ceramides in NAFLD.
Poss AM; Summers SA
Front Endocrinol (Lausanne); 2020; 11():505. PubMed ID: 32849291
[TBL] [Abstract][Full Text] [Related]
18. Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis.
Alonso C; Fernández-Ramos D; Varela-Rey M; Martínez-Arranz I; Navasa N; Van Liempd SM; Lavín Trueba JL; Mayo R; Ilisso CP; de Juan VG; Iruarrizaga-Lejarreta M; delaCruz-Villar L; Mincholé I; Robinson A; Crespo J; Martín-Duce A; Romero-Gómez M; Sann H; Platon J; Van Eyk J; Aspichueta P; Noureddin M; Falcón-Pérez JM; Anguita J; Aransay AM; Martínez-Chantar ML; Lu SC; Mato JM
Gastroenterology; 2017 May; 152(6):1449-1461.e7. PubMed ID: 28132890
[TBL] [Abstract][Full Text] [Related]
19. Increased serum concentration of ceramides in obese children with nonalcoholic fatty liver disease.
Wasilewska N; Bobrus-Chociej A; Harasim-Symbor E; Tarasów E; Wojtkowska M; Chabowski A; Lebensztejn DM
Lipids Health Dis; 2018 Sep; 17(1):216. PubMed ID: 30208901
[TBL] [Abstract][Full Text] [Related]
20. Concise review of lipidomics in nonalcoholic fatty liver disease.
Béland-Bonenfant S; Rouland A; Petit JM; Vergès B
Diabetes Metab; 2023 May; 49(3):101432. PubMed ID: 36781065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
